World PEGylated Proteins Analysis Report 2023-2028: Increasing Utilization of Protein Drugs in Hematology and Oncology Bodes Well for the Market - ResearchAndMarkets.com
The global market for PEGylated proteins is expected to grow from $10.2 billion in 2023 and is projected to reach $15.9 billion by the end of 2028, at a compound annual growth rate (CAGR) of 9.4% during the forecast period of 2023 to 2028.
This report highlights the current and future market potential of PEGylated proteins and provides a detailed analysis of the drivers, restraints, and opportunities in this market. The report also surveys the competitive environment for PEGylated proteins, including coverage of the pipeline activities adopted by players in this market, and it includes market projections for 2028. Also included are company profiles of key players featuring detailed information about each company's business segments, financials, product portfolios and recent developments. The report does not cover PEGylated vaccines.
In this report, the global market for PEGylated proteins market is segmented into four regions: North America, Europe, Asia-Pacific and the Rest of the World. For market estimates, data is provided for 2020 and 2021 (which serve as the historic years), for 2022 (the base year), and forecast for 2028.
Report Includes
41 data tables and 22 additional tables
Analysis of the PEGylated proteins market
Analyses of global market trends, with revenue data for 2021-2022, estimates for 2023, forecasts for 2024, and projected CAGRs through 2028
Estimates of the current market size and revenue growth prospects, along with a market share analysis by product and services, protein type, application, and region
Facts and figures pertaining to the market drivers, opportunities and restraints, and the impact of macroeconomic variables
An analysis of recent patent grants and published patents
A look at emerging technologies and regulatory issues
Overview of sustainability trends and ESG developments, including consumer attitudes, companies' ESG score rankings and their ESG practices
Insight into the competitive landscape, including companies' market shares, business segments, financials and product portfolios, as well as recent M&A activity and venture funding outlook
Company Profiles
Amgen Inc.
F. Hoffmann-La Roche Ltd.
Merck Kgaa
Pfizer Inc.
Sandoz Group Ag
Key Attributes:
Report Attribute
Details
No. of Pages
74
Forecast Period
2023 - 2028
Estimated Market Value (USD) in 2023
$10.2 Billion
Forecasted Market Value (USD) by 2028
$15.9 Billion
Compound Annual Growth Rate
9.4%
Key Topics Covered:
Chapter 1 Executive Summary
Market Outlook
Scope of Report
Market Summary
Chapter 2 Market Overview
Introduction
Advantages of Protein PEGylation
Limitations of PEGylated Therapeutics
Chapter 3 Market Dynamics
Market Dynamics Snapshot
Market Drivers
Protein Drugs in Hematology and Oncology
Design of Biobetters
Market Restraints
Immunogenicity and Side Effects
Formulation Challenges
Market Opportunities
Site-Specific PEGylation
New Indications and Formulation Techniques
Chapter 4 Emerging Technologies and Developments
Introduction
Non-Covalent PEGylation
PEGylation of Nanoparticles
Antibody-Drug Conjugates (ADCs)
Chapter 5 Market Segmentation Analysis
Segmentation Breakdown
Global PEGylated Proteins Market, by Protein Type
Granulocyte-Colony Stimulating Factors (G-CSF)
PEGylated Monoclonal Antibodies
PEGylated Interferons
PEGylated Recombinant Factors
Other Protein Types
Global PEGylated Proteins Market, by PEGylation Type
Linear PEGylated Proteins
Branched PEGylated Proteins
Global PEGylated Proteins Market, by PEGylation Application
Autoimmune Diseases
Hematology
Cancer
Other Applications
Geographic Breakdown
Global Market for PEGylated Proteins, by Region
North America
Europe
Asia-Pacific
Rest of the World
Chapter 6 Competitive Intelligence
Recent Developments in the PEGylated Proteins Market
Clinical Trial Activities
Chapter 7 Sustainability in the PEGylated Proteins Market: ESG Perspective
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Today, NJOY, an Altria company, announces the submission of a supplemental Premarket Tobacco Product Application (PMTA) to the U.S. Food and Drug Administration (FDA) to commercialize and market the NJOY ACE 2.0 device. This new device incorporates...
Rubicon Technologies, Inc. ("Rubicon" or the "Company") , a leading provider of technology solutions for waste and recycling generators, today reported financial and operational results for the first quarter of 2024.
First Quarter 2024 Financial...
American Public Education, Inc. , a portfolio of education companies providing online and campus-based postsecondary education and career learning to over 125,000 students through four subsidiary institutions, today announced that management will be...
Remark Holdings, Inc. , a leading provider of artificial intelligence solutions, today announced its financial results for its quarter ended March 31, 2024. For complete details of the consolidated financial statements and accompanying management's...
South Atlantic Bancshares, Inc. ("South Atlantic" or the "Company") , parent of South Atlantic Bank (the "Bank"), today announced that the board of directors of the Company (the "Board") has authorized a stock repurchase program for up to 380,341 of...
Pulse Biosciences, Inc. ("Pulse" or the "Company"), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablationtm (nsPFAtm) technology, today announced that the Company's Board of Directors has determined a new record...